Status:
RECRUITING
TESTING -ON Post-Trial ObservatioNal Cohort Study
Lead Sponsor:
The George Institute
Collaborating Sponsors:
Peking University Institute of Nephrology
Conditions:
IgA Nephropathy
ESRD
Eligibility:
All Genders
18-100 years
Brief Summary
The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESK...
Detailed Description
In the original TESTING study, the median follow-up for full vs reduced dose cohort was 6.1 vs 2.5 years. We learned from the TESTING trial that the composite endpoints (ESKD, 40% reduction in eGFR or...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 1\) Only participants who were randomised into the TESTING trial
- Exclusion Criteria
- Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial
- Participants who died during the TESTING trial
- Participants who had withdrawn their consent during the TESTING trial
- Participants who are unable to provide consent for some other reason
Exclusion
Key Trial Info
Start Date :
December 7 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 30 2027
Estimated Enrollment :
366 Patients enrolled
Trial Details
Trial ID
NCT05434325
Start Date
December 7 2022
End Date
July 30 2027
Last Update
February 11 2025
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Nepean Hospital
Kingswood, New South Wales, Australia, 2747
2
Royal North Shore Hospital
St Leonards, New South Wales, Australia, 2065
3
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
4
University of Calgary/Alberta Health Services
Calgary, Alberta, Canada, T2R 0X7